Mayne Pharma and IDT Launch Temozolomide Capsules in the US

Mayne Pharma (ASX:MYX) today announces the American launch of IDT’s temozolomide capsules, a generic version of Temodar. Mayne Pharma will distribute the drug for IDT Australia.
According to the press release:

“Temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.”

Scott Richards, CEO of Mayne Pharma, said the following:

“Since entering the United States in 2012, Mayne Pharma has aggressively expanded its product portfolio, through internal product development, strategic acquisition, in-licensing and working collaboratively with partners like IDT.”

Read the full press release here.